Gastrointestinal cancer articles from across Nature Portfolio

Transplantation for non-resectable colorectal liver metastasis (CRLM) has become accepted for a few, select patients following stringent criteria. With improved understanding of the selective indications, enhanced curation of the donor pool, and by further insight into cancer biology, novel avenues for research may be developed and eventually benefit more patients with non-resectable CRLM.

Allele-specific inhibitors of KRAS^G12C are approved in non-small-cell lung cancer. Herein, we discuss recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRAS^G12C-mutant metastatic colorectal cancer. The combination had promising efficacy and, if confirmed in later-phase trials, concomitant inhibition of EGFR and KRAS^G12C will present a new paradigm in precision oncology.

Neoadjuvant chemotherapy offers a pragmatic alternative to the difficulties associated with delivering timely adjuvant chemotherapy in rectal cancer. Enthusiasm for administering neoadjuvant therapy to all patients with locally advanced rectal cancer is based on data from several phase III trials. Data from the RAPIDO trial are a critical component of this evidence.